- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04876053
Entrega de comida em domicílio para controle de diabetes em pacientes de clínicas rurais
Nosso objetivo de longo prazo é transformar a gestão de T2DM dos residentes rurais. O objetivo deste estudo é determinar a eficácia de uma intervenção que seja escalável e sustentável e promova a adesão do paciente ao mitigar as dificuldades dos participantes com insegurança alimentar rural associadas à conclusão das intervenções existentes. Nossos objetivos específicos são:
- Comparar a eficácia da Intervenção de Fornecimento de Alimentos Saudáveis (HFDI) mais o tratamento padrão e o atendimento padrão sozinho para melhorar os resultados relacionados ao diabetes entre pacientes com DMT2 com insegurança alimentar rural. Hipótese: Comparado apenas com o tratamento padrão, os pacientes que recebem o HFDI mais o tratamento padrão demonstrarão melhora: controle glicêmico H1 medido por HbA1c; Fatores de risco cardiometabólico H2: pressão arterial, glicose em jejum, lipídios em jejum e IMC; H3 autogestão: autoeficácia, adesão aos comportamentos de autogestão e adesão à medicação; Desfechos centrados no paciente H4: angústia relacionada ao diabetes, qualidade de vida relacionada ao diabetes e complicações relacionadas ao diabetes.
- Comparar a eficácia do HFDI mais o tratamento padrão e o tratamento padrão sozinho para melhorar a qualidade da dieta entre pacientes com DMT2 com insegurança alimentar rural. Hipótese: Comparado apenas com o tratamento padrão, os pacientes que recebem o HFDI mais o tratamento padrão demonstrarão melhora: pontuações H1 do Índice de Alimentação Saudável 2015 (HEI-2015); H2 consumo de frutas e vegetais.
- Compare o custo-efetividade para entender o HFDI mais os custos do tratamento padrão em relação aos resultados em relação ao tratamento padrão sozinho. Hipótese: O HFDI será custo-efetivo com base no custo tradicional por ano de vida adicional ajustado pela qualidade ganho.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Type 2 diabetes mellitus (T2DM) is a growing public health concern affecting 37.3 million people (11.3%) in the United States (US). At the same time, 13.5 million (10.2%) US households experience food insecurity. People living in rural areas are particularly challenged by the intersection of food insecurity and T2DM - both food insecurity and T2DM prevalence in rural areas are higher than metropolitan areas. Arkansas has the sixth highest proportion of rural population (44.5%) of all US states, with rates of food insecurity and T2DM of 14.7% and 12.5%, respectively. Rurality and food insecurity are associated with social determinants of health that impede diabetes management (e.g., limited transportation, longer distance to healthcare clinics, lack of access to healthy food options). People experiencing food insecurity have poor diet quality (e.g., high intake of sugar-sweetened beverages and red/processed meat, low intake of fruits and vegetables), which is a key risk factor for unmanaged T2DM. Unmanaged T2DM can lead to increased risk of serious complications. Improved diet quality is a crucial factor to enhance T2DM management. Millions of people with T2DM experiencing food insecurity turn to food pantries for food; however, food pantries are not a long-term solution to improve health for rural people with T2DM experiencing food insecurity. Certified Diabetes Care and Education Specialists (CDCES; i.e., diabetes educators) have expertise in working with patients to instill knowledge and skills necessary to live an active and healthy lifestyle with T2DM.
This study used a two-arm randomized controlled comparative effectiveness design to compare the effectiveness of a Healthy Food Delivery Intervention (HFDI) plus a consultation with a CDCES Consultation Only in improving diabetes-related outcomes among rural people with T2DM experiencing food insecurity. We hypothesized HFDI to be comparatively more effective in improving HbA1c and other outcomes for rural people with T2DM experiencing food insecurity.
The primary outcome was change in hemoglobin A1c (HbA1c) between baseline and post-intervention. Secondary outcomes included diet quality (Healthy Eating Index-2015 and Veggie meter scores), body mass index, blood pressure, lipids, glucose, diabetes management self-efficacy and diabetes-related distress. We also examined the duration of treatment effects by comparing outcomes at 6 months post-intervention and 12 months post-intervention.
Participants were randomly assigned to either the HFDI arm or the CDCES Consultation Only arm. Participants randomized to the CDCES Consultation Only study arm received the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a CDCES and a food pantry resource guide specific to their community. In addition to standard of care and the CDCES consultation, participants randomized to the HFDI arm received weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total). Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.
Participants were initially recruited only from family medicine clinics within the University of Arkansas for Medical Sciences (UAMS) network that serve the highest percentage of rural patients with T2DM. Additional clinics and Federally Qualified Health Centers were added as recruitment sites in order to meet study recruitment goals.
Inclusion criteria included: 1) 18 years of age or older; 2) food insecure (Hunger Vital Sign™ 2-item screener); 3) HbA1c ≥ 6.5%; 4) speak English or Spanish; and 5) live at a rural address. Note: the food insecurity and rural residence criteria were removed during the course of the study in order to meet study recruitment goals.
Exclusion criteria included: 1) having conditions making it unlikely the participant will be able to follow the protocol, such as terminal illness, severe mental illness, severely impaired vision or hearing, eating disorder, or plans to move out of the geographic region; 2) pregnant; 3) only one adult with T2DM per household was allowed to enroll.
Investigators worked with clinical stakeholders at each clinic site to ensure the study was integrated into existing workflows. Study flyers were placed throughout the clinics, in the exam rooms, and in the clinic waiting areas. All clinics had electronic health record systems that were queried monthly for recruitment. Research coordinators at each clinic site identified potential participants by reviewing monthly patient queries and daily clinic schedules. The research coordinators provided study information to potential participants in a pre-visit call or during the clinical visit. If the patient was interested, the research coordinator scheduled a 30-minute meeting to discuss the study and conduct eligibility screening in a private room in the clinic. Research staff were trained to flag potential participants that may not meet eligibility, which were then sent to the study physician for medical determination. Those deemed eligible to participate reviewed study information with the research coordinator, were given the chance to ask questions, and signed an informed consent. All recruitment and consent information was available in English and Spanish.
Randomization was conducted by the study biostatistician, who had no interactions with potential participants and no supervisory role with study staff responsible for recruiting, consent, and intervention processes. Stratified random assignment using permuted blocks of size 2, 4, and 6 was used to randomize participants 1:1 to the treatment arms using lists created with the blockrand R package. Strata of participant sex, level of T2DM control (6.5-9.0%; >9.0%), and age group (18-64; 65+ years) were used to ensure that similar numbers within each characteristic are assigned 1:1 to the treatment arms.
Data collection occurred in-person at the clinic from which participants were recruited, co-occurring with participants' primary care provider visits when possible. Biometric and survey measure outcomes were collected at baseline (pre-intervention), immediate post-intervention (approximately 18 weeks after baseline), 6 months post-intervention, and 12 months post-intervention.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Arkansas
-
Batesville, Arkansas, Estados Unidos, 72501
- UAMS - North Central
-
Corning, Arkansas, Estados Unidos, 72422
- Pocahontas Medical Center
-
Eureka Springs, Arkansas, Estados Unidos, 72632
- Washington Regional Medical Center
-
Fayetteville, Arkansas, Estados Unidos, 72703
- Washington Regional Medical Center
-
Fayetteville, Arkansas, Estados Unidos, 72703
- UAMS - Northwest
-
Fort Smith, Arkansas, Estados Unidos, 72901
- UAMS - West
-
Harrison, Arkansas, Estados Unidos, 72601
- Washington Regional Medical Center
-
Helena, Arkansas, Estados Unidos, 72390
- UAMS - East
-
Jonesboro, Arkansas, Estados Unidos, 72401
- UAMS - Northeast
-
Magnolia, Arkansas, Estados Unidos, 71753
- UAMS - South
-
Marianna, Arkansas, Estados Unidos, 72360
- Lee County Cooperative Clinic
-
Marshall, Arkansas, Estados Unidos, 72650
- Boston Mountain Rural Health Center
-
Pocahontas, Arkansas, Estados Unidos, 72455
- Pocahontas Medical Clinic
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Descrição
Critério de inclusão:
- 18 anos de idade ou mais
- denunciar insegurança alimentar
- relatório T2D (confirmado por ter um HbA1c igual ou superior a 6,5 na coleta de dados inicial imediatamente após o consentimento)
- Fala ingles ou Espanhol
- Atualmente mora em um endereço rural
Critério de exclusão:
- condições que tornam improvável que o participante seja capaz de seguir o protocolo, como doença terminal, doença mental grave, visão ou audição gravemente prejudicada, distúrbio alimentar ou planos de sair da região geográfica
- Grávida
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: CDCES Consultation Only
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
|
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
|
|
Experimental: Healthy Food Delivery Intervention
In addition to standard of care and the CDCES consultation, participants randomized to the Healthy Food Delivery arm receive weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).
|
Participants randomized to the Healthy Food Delivery Intervention receive standard of care, a CDCES Consultation, food pantry resource guide, and weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).Each food box included approximately 9000 calories of food.
Food boxes were designed by a Registered Dietician.
Food boxes also included recipes and cooking tips specific to foods included in that week's box.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hemoglobin A1c (HbA1c)
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Finger stick blood collection will be used to test HbA1c using a Siemens DCA Vantage analyzer.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diet Quality: Healthy Eating Index-2015 Score
Prazo: Baseline; Immediate post-intervention
|
Diet quality was assessed with a 24-hour dietary recall interview using the Nutrition Data System for Research (NDSR) software.
The Healthy Eating Index-2015 (HEI) was applied to the dietary recall data to measure the extent that dietary intake among participants met the Dietary Guidelines for Americans 2015-2020 recommendations.
HEI-2015 consists of 13 individual components.
HEI-2015 scores have a possible range of 0-100, with higher numbers indicating better diet quality.
|
Baseline; Immediate post-intervention
|
|
Diet Quality: Veggie Meter Score
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Skin carotenoid level was measured using a Veggie Meter optical skin scanner, which uses Raman Spectroscopy.
The Veggie Meter assesses frequency changes in reflected light to calculate carotenoid presence in the skin and has been validated as a non-self-report, non-invasive measure associated with serum carotenoid levels and self-report measures of fruit and vegetable consumption.
Each participant's index finger was scanned three times and the mean of the three measures was recorded for use in data analysis.
Veggie Meter scores have a possible range of 0-800, with higher scores indicating better diet quality.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Body Mass Index (BMI)
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Participant height (without shoes) was collected using a stadiometer and participant weight (without shoes) was collected using a calibrated digital scale.
Height and weight were used to compute a continuous measure of BMI (kilograms per square meter).
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Systolic Blood Pressure (SBP)
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height.
Two blood pressure measurements were taken, waiting at least one minute between readings.
If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken.
The mean of the two (or four) measurements was recorded and used in analysis.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Diastolic Blood Pressure (DBP)
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height.
Two blood pressure measurements were taken, waiting at least one minute between readings.
If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken.
The mean of the two (or four) measurements was recorded and used in analysis.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Total Cholesterol
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect lipids using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
High-Density Lipoproteins (HDL)
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Low-Density Lipoproteins (LDL)
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect LDL using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Triglycerides
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Glucose
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect random (non-fasting) blood glucose.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Diabetes Self-Efficacy (DMSES)
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
The Diabetes Management Self-Efficacy Scale (DMSES) was used to measure patient's confidence in managing their diabetes.
The DMSES assesses self-reported confidence in managing multiple aspects of their diabetes.
The item reponses range from 1 (not at all confident) to 10 (totally confident) and are averaged to generate composite scores, with higher scores indicating higher levels of self-efficacy.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Diabetes-Related Distress (PAID-5)
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
The Problem Areas in Diabetes scale (PAID-5) was used to measure diabetes-related distress.
The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed.
Item responses range from 0 (not a problem) to 4 (serious problem) and are summed to produce an overall composite score, with a total score of 8 or higher indicating possible diabetes-related emotional distress.
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
|
Food Insecurity
Prazo: Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Food insecurity was assessed using the 2-item Hunger Vital Sign.
Affirmative answers ("Often True" or "Sometimes True") to either of the 2 screener items indicates food insecurity.
Food insecurity was treated as a binary outcome (0=food secure, 1=food insecure).
|
Baseline; Immediate post-intervention; 6 months post-intervention; 12 months post-intervention
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Pearl A McElfish, PhD, University of Arkansas
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 261074
- 5R01NR019487 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .